PSNL Jumps As Personalis Agrees To Tempus AI Buyout
Personalis Inc. (PSNL) stock rose 9.41% after agreeing to be acquired by Tempus AI for $16.25 per share. Q2 revenue was $22.4M, up 199% YoY, but the company remains unprofitable. Analysts see $16.25 as strong support and $19–20 as resistance.
How this was made
The 30-second read
Why it matters
The acquisition provides a clear exit valuation, turning a volatile micro‑cap into a merger‑arb trade with defined risk/reward.
Market read
The announcement drives immediate price action and creates a short‑term trading opportunity in the biotech sector.
What to watch
Potential for a higher competing bid from larger diagnostics players could push price above the agreed $16.25.
Background
Personalis operates in minimal residual disease (MRD) testing; the company has been loss‑making but shows strong revenue growth.
Ticker impact
Personalis Inc. agreed to be acquired by Tempus AI at $16.25 per share, a fresh M&A announcement driving a 9.4% price jump.
Expect PSNL to trade near the deal price range $16.25‑$18.50, with limited upside unless a higher bid appears.
The acquisition price is disclosed for the first time, market has already re‑rated the stock, and merger‑arb dynamics are clear.
Market effects
The deal underscores consolidation in oncology genomics and may trigger valuation reassessments for peer diagnostics firms.
US biotech sector sees modest uplift as merger‑arb opportunities attract short‑term traders.
Limited to US‑listed biotech; no broader macro effect.
Counterpoint
If regulatory or fairness‑review hurdles delay closing, PSNL could fall below $16.25, rewarding short positions.
Key entities
- CompanyPersonalis Inc.
US‑listed biotech (NASDAQ: PSNL) targeted for acquisition.
- CompanyTempus AI
Acquirer offering $16.25 per share.
